Alphagan P (brimonidine tartrate) adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Alphagan P
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Brand name
Generic name: Brimonidine tartrate
Class: alpha-Adrenergic agonist

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Drug reports received through 30 Jun 2026. Device reports have a separate cutoff, 30 Sep 2026. Why a report count is not a rate.

Reports on file

From February 2004 to June 2026, FDA received 2,656 adverse event reports that name Alphagan P. In these reports the drug is a suspect or interacting product.

In the same period, 3,445 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 110 reports in the 12 months to June 2026 and 117 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 110 (under 0.1%) name Alphagan P. Reports from consumers or other non-health professionals were 64.8% of the reports that name Alphagan P and 45.8% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Alphagan P is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

The latest update of the FDA data, recorded on 28 Oct 2026, changed no count of this page.

In April to June 2026, FDA received 30 reports that name Alphagan P.
In January to March 2026, FDA received 30.
In April to June 2025, FDA received 26.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 200 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 2,629 of the 2,656 reports (99%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 200 terms.

Reaction terms in the reports that name Alphagan P, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 2,656 reports
Ocular hyperaemiaa red eye	317	11.9%
Eye irritation	264	9.9%
Drug ineffectivethe medicine did not work as expected	231	8.7%
Intraocular pressure increasedraised pressure in the eye	204	7.7%
Inappropriate schedule of drug administrationthe medicine was taken at the wrong times	199	7.5%
Vision blurredblurred vision	173	6.5%
Eye pain	163	6.1%
Eye pruritus	154	5.8%
Hypersensitivityan allergic-type reaction	138	5.2%
Drug hypersensitivityan allergic-type reaction (the term names a medicine)	115	4.3%
Off label useused for a purpose or in a way not on the label	109	4.1%
Visual impairmentreduced vision	95	3.6%
Product storage errorthe product was stored wrongly	94	3.5%
Dizzinesslight-headedness or unsteadiness	89	3.4%
Corneal opacity	87	3.3%
Erythemaskin redness	87	3.3%
Dry eye	86	3.2%
Eye swellinga swollen eye	83	3.1%
Headachehead pain	79	3%
Fatiguetiredness	75	2.8%
Incorrect dose administeredthe wrong dose was given	72	2.7%
Eye discharge	69	2.6%
Accidental exposure to product	66	2.5%
Lacrimation increasedwatery eyes	66	2.5%
Glaucomaraised pressure in the eye	61	2.3%
Cataractclouding of the eye lens	59	2.2%
Somnolencedrowsiness	59	2.2%
Visual acuity reducedreduced sharpness of vision	58	2.2%
Condition aggravatedthe condition being treated got worse	57	2.1%
Eye disorder	55	2.1%
Treatment failurethe treatment did not work	53	2%
Dry mouth	51	1.9%
Product container issuea problem with the container	50	1.9%
Conjunctivitispink eye	49	1.8%
Inappropriate schedule of product administrationthe product was taken at the wrong times	48	1.8%
Drug dose omissiona dose was missed	47	1.8%
Foreign body sensation in eyes	45	1.7%
Drug intolerancethe medicine was not tolerated	44	1.7%
Hypotensionlow blood pressure	43	1.6%
Pruritusitching	43	1.6%
Erythema of eyelid	42	1.6%
Hypertensionhigh blood pressure	41	1.5%
Product packaging quantity issue	38	1.4%
Abdominal painstomach or belly pain	37	1.4%
Cough	37	1.4%
Product dose omissiona dose was missed	37	1.4%
Blindnessloss of sight	36	1.4%
Coma	35	1.3%
Dyspnoeashortness of breath	35	1.3%
Hypothyroidismunderactive thyroid	35	1.3%

Download all 200 terms of Alphagan P (CSV)

The counts add to more than 2,656 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Same ingredient, other names

Reporters write a brand name or a generic name. Each name has its own page and its own count.

Names of Brimonidine with a page, in the order generic names, brand names, names as reported
Name	Name type	Reports
Brimonidine	Generic name	4,285
Brimonidine tartrate	Generic name	1,012
Alphagan P (this page)	Brand name	2,656
Mirvaso	Brand name	926

Sum of the separately reported names: 8,879. A report that names two of these names is in the sum two times. The sum is not the number of reports for the ingredient.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Alphagan P, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Congenital Anomaly/Birth Defect	Other Serious (Important Medical Events)	Not serious
2004	5	5	0	0	2	1	0	2	0
2005	6	5	1	1	1	1	0	1	1
2006	8	7	0	0	4	0	0	3	1
2007	8	5	1	0	1	0	0	3	3
2008	20	8	0	1	2	0	0	7	12
2009	56	8	1	0	1	1	0	6	48
2010	14	9	0	0	1	2	0	7	5
2011	15	8	0	0	0	0	0	8	7
2012	105	10	1	0	3	2	0	7	95
2013	133	11	1	0	1	1	0	9	122
2014	183	44	3	1	6	2	0	34	139
2015	235	81	3	0	24	8	0	53	154
2016	274	80	3	0	13	8	0	64	194
2017	262	82	1	2	25	7	2	55	180
2018	170	35	2	3	5	5	0	23	135
2019	212	61	0	2	16	3	0	52	151
2020	263	86	0	8	17	1	0	71	177
2021	164	53	2	3	10	5	0	41	111
2022	107	48	3	3	9	12	1	31	59
2023	112	44	6	0	8	6	0	30	68
2024	125	74	6	1	12	5	1	60	51
2025	116	52	7	1	6	3	1	41	64
2026	63	32	1	0	10	2	0	25	31

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Alphagan P, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Alphagan P, by the year in which FDA received them
Year	Reports
2004	4
2005	6
2006	8
2007	9
2008	10
2009	68
2010	12
2011	15
2012	109
2013	135
2014	188
2015	248
2016	296
2017	246
2018	166
2019	221
2020	273
2021	139
2022	94
2023	113
2024	125
2025	111
2026	60

Reports that name Alphagan P, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Alphagan P
Age	Reports	Share
Under 2	7	0.3%
2 to 11	2	0.1%
12 to 17	1	under 0.1%
18 to 44	34	1.3%
45 to 64	281	10.6%
65 to 74	307	11.6%
75 and over	497	18.7%
Age not given	1,527	57.5%

Sex of the patient in the reports that name Alphagan P
Sex	Reports	Share
Female	1,660	62.5%
Male	818	30.8%
Unknown or not given	178	6.7%

Type of reporter in the reports that name Alphagan P
Reporter	Reports	Share
Physician	565	21.3%
Pharmacist	94	3.5%
Other health professional	233	8.8%
Lawyer	1	under 0.1%
Consumer or non-health professional	1,720	64.8%
Not given	43	1.6%

Age and sex are as the report gives them. The reporter is the primary source in the report. 82.1% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Alphagan P record
Indication as recorded (MedDRA)	Reports	Share
Glaucoma	1,070	40.3%
Intraocular pressure increased	239	9%
Open angle glaucoma	68	2.6%
Intraocular pressure test	44	1.7%
Normal tension glaucoma	23	0.9%
Ocular hypertension	16	0.6%

The reporter fills in the indication, and the field is often empty. Each share is of all 2,656 reports.

Drugs in the same reports

Other drugs that the reports of Alphagan P name, in any role, in order of name
Drug	Reports that name the two
Azopt	105
Combigan	72
Dorzolamide	64
Latanoprost	202
Lumigan	400
Timolol	62
Timolol maleate	67
Travatan	93
Travatan Z	68
Xalatan	168

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Brimonidine same ingredient
Brimonidine tartrate same ingredient
Mirvaso same ingredient
Alavert same class
Claritin-D same class
Alphagan next in the A to Z list
Alprazolam next in the A to Z list
Alpha -Tocopherol D- next in the A to Z list
Alprolix next in the A to Z list
Alpelisib next in the A to Z list
Alprostadil next in the A to Z list
Aloxi next in the A to Z list

These links are for navigation. No count selected them. The class page lists each drug of the class.

Official pages

DailyMed labels for Alphagan PThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Alphagan P: adverse event reports that FDA received. https://reportedreactions.com/drug/alphagan-p/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Alphagan P as a suspect or interacting product. The 3,445 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Alphagan P was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Alphagan P?

No. It is a count of what people reported to FDA: 2,656 reports from February 2004 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Consumer or non-health professional (64.8%), physician (21.3%) and other health professional (8.8%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page